TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

289

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Multiple Myeloma in RelapseRefractory Multiple Myeloma
Interventions
DRUG

TJ202, Lenalidomide and Dexamethasone

One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.

DRUG

Lenalidomide and Dexamethasone

Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.

Trial Locations (41)

100

National Taiwan University Hospital, Taiwan

114

Tri-Service General Hospital, Taiwan

833

Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Taiwan

40705

Taichung Veterans General Hospital, Taiwan

100020

Capital Medical University (CMU) - Beijing Chao-Yang Hospital, Beijing

100083

Peking University Third Hospital, Beijing

110001

The First Hospital of China Medical University, Shenyang

130021

The First Bethune Hospital of Jilin University, Jilin

200000

Shanghai Changzheng Hospital, Shanghai

200025

Shanghai Jiao Tong University School of Medicine - Ruijin Hospital, Shanghai

200233

Shanghai Sixth People's Hospital, Shanghai

210008

Nanjing Drum Tower Hospital, Nanjing

210029

Jiangsu Province Hospital, Nanjing

215006

The First Affiliated Hospital of Soochow University, Suzhou

300052

Tianjin Medical University General Hospital, Tianjin

300060

Tianjin Cancer Hospital, Tianjin

310003

The First Affiliated Hospital of Zhejiang University, Zhejiang

325000

The First Affiliated Hospital of Wenzhou Medical University, Zhejiang

330006

Second Affiliated Hospital of Nanchang University, Jiangxi

350001

Fujian Medical University Union Hospital, Fujian

430014

The Central Hospital Of Wuhan, Hubei

450008

Henan Cancer Hospital, Henan

510060

Sun Yat-Sen University Cancer Center, Guangdong

510080

Guangdong General Hospital, Guangdong

510180

Guangzhou First People's Hospital, Guangdong

510515

Nanfang Hospital, Guangdong

518035

Shenzhen Second Hospital, Guangdong

530021

Guangxi Medical Univ. 1st Hospital, Guangxi

650101

The second affiliated hospital of Kunming medical university, Yunnan

650221

The First People's Hospital of Yunnan Province, Yunnan

730000

The First Hospital of Lanzhou University, Lanzhou

730030

Lanzhou University Second Hospital, Lanzhou

Unknown

Capital Medical University (CMU) - Beijing Chao-Yang Hospital, Beijing

The First Affiliated Hospital of Bengbu Medical college, Bengbu

Hunan Cancer Hospital, Hunan

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

The First Affiliated Hospital of Zhejiang University, Zhejiang

Hubei Cancer Hospital, Wuhan

Affiliated Hospital of Nantong University, Nantong

Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
lead

TJ Biopharma Co., Ltd.

INDUSTRY

NCT03952091 - TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter